Ontology highlight
ABSTRACT:
SUBMITTER: Musielak B
PROVIDER: S-EPMC6695792 | biostudies-literature | 2019 Aug
REPOSITORIES: biostudies-literature
Molecules (Basel, Switzerland) 20190801 15
<b>CA-170</b> is currently the only small-molecule modulator in clinical trials targeting PD-L1 and VISTA proteins - important negative checkpoint regulators of immune activation. The reported therapeutic results to some extent mimic those of FDA-approved monoclonal antibodies overcoming the limitations of the high production costs and adverse effects of the latter. However, no conclusive biophysical evidence proving the binding to hPD-L1 has ever been presented. Using well-known in vitro method ...[more]